Prostate cancer continues to be the second-leading cause of cancer death in men, with over 230,000 men diagnosed with prostate cancer each year. When someone is diagnosed with prostate cancer, the effects of the disease often reach to friends and family, particularly a wife or partner. The diagnosis, treatment and side effects of prostate cancer affect the surrounding family as […]
Category: Prostate Cancer Blog
The Prostate Cancer Awareness Project (PCAP) is a non-profit charity group based in Manhattan Beach, CA. They work to create prostate cancer awareness events, free screening programs and the innovative “Visual Prostate Cancer Detection System.” A visual way for men to track their prostate and PSA levels over time. There are an estimated 30,000 American men […]
Beckman Coulter, Inc, leader in prostate cancer diagnostics has announced the Premarket Approval from the U.S. Food and Drug Administration (FDA) on the new Prostate Health Index (phi) blood test. The new approved PHI test is 2.5x’s more specific in detecting prostate cancer than the controversial PSA test. It has shown a 31 percent reduction in […]
Today marks the first day of Men’s Health Month. Each June organizations, individuals, workplaces, communities, government agencies and places of worship come together to raise awareness of preventable health problems and encourage early detection and treatment of disease among men, boys, and their families. Awareness periods like this help end the silence surrounding men’s health and […]
Congrats to our Western New York Chapter President, Joan Peck who recently had her article, “We Have Prostate Cancer” published in Women Magazine. In the article she discusses the journey she took with her husband after his prostate cancer diagnosis and the top 10 things that women should know about prostate cancer. Check out the […]
We need your help! The vital Prostate Cancer Research Program (PCRP) at the Department of Defense is under threat of being eliminated.
The Centers for Medicare and Medicaid Services (CMS) is currently accepting public comments on the proposed national coverage determination for the first ever immunotherapy treatment for prostate cancer, Provenge.